These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

981 related articles for article (PubMed ID: 28835125)

  • 1. Small But Increasingly Mighty: Latest Advances in AAV Vector Research, Design, and Evolution.
    Grimm D; Büning H
    Hum Gene Ther; 2017 Nov; 28(11):1075-1086. PubMed ID: 28835125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next-generation AAV vectors for clinical use: an ever-accelerating race.
    Weinmann J; Grimm D
    Virus Genes; 2017 Oct; 53(5):707-713. PubMed ID: 28762205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Boosters for adeno-associated virus (AAV) vector (r)evolution.
    Szumska J; Grimm D
    Cytotherapy; 2023 Mar; 25(3):254-260. PubMed ID: 35999132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next-generation AAV vectors-do not judge a virus (only) by its cover.
    Domenger C; Grimm D
    Hum Mol Genet; 2019 Oct; 28(R1):R3-R14. PubMed ID: 31261383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relevance of Assembly-Activating Protein for Adeno-associated Virus Vector Production and Capsid Protein Stability in Mammalian and Insect Cells.
    Grosse S; Penaud-Budloo M; Herrmann AK; Börner K; Fakhiri J; Laketa V; Krämer C; Wiedtke E; Gunkel M; Ménard L; Ayuso E; Grimm D
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28768875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Production, Processing, and Characterization of Synthetic AAV Gene Therapy Vectors.
    El Andari J; Grimm D
    Biotechnol J; 2021 Jan; 16(1):e2000025. PubMed ID: 32975881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tracking Adeno-Associated Virus Capsid Evolution by High-Throughput Sequencing.
    de Alencastro G; Pekrun K; Valdmanis P; Tiffany M; Xu J; Kay MA
    Hum Gene Ther; 2020 May; 31(9-10):553-564. PubMed ID: 32024384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineering and evolution of synthetic adeno-associated virus (AAV) gene therapy vectors via DNA family shuffling.
    Kienle E; Senís E; Börner K; Niopek D; Wiedtke E; Grosse S; Grimm D
    J Vis Exp; 2012 Apr; (62):. PubMed ID: 22491297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expressing Transgenes That Exceed the Packaging Capacity of Adeno-Associated Virus Capsids.
    Chamberlain K; Riyad JM; Weber T
    Hum Gene Ther Methods; 2016 Feb; 27(1):1-12. PubMed ID: 26757051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-Throughput Dissection of AAV-Host Interactions: The Fast and the Curious.
    Herrmann AK; Grimm D
    J Mol Biol; 2018 Aug; 430(17):2626-2640. PubMed ID: 29782834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isolation of Next-Generation Gene Therapy Vectors through Engineering, Barcoding, and Screening of Adeno-Associated Virus (AAV) Capsid Variants.
    Rapti K; Maiakovska O; Becker J; Szumska J; Zayas M; Bubeck F; Liu J; Gerstmann E; Krämer C; Wiedtke E; Grimm D
    J Vis Exp; 2022 Oct; (188):. PubMed ID: 36342179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coevolution of Adeno-associated Virus Capsid Antigenicity and Tropism through a Structure-Guided Approach.
    Havlik LP; Simon KE; Smith JK; Klinc KA; Tse LV; Oh DK; Fanous MM; Meganck RM; Mietzsch M; Kleinschmidt J; Agbandje-McKenna M; Asokan A
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32669336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping an Adeno-associated Virus 9-Specific Neutralizing Epitope To Develop Next-Generation Gene Delivery Vectors.
    Giles AR; Govindasamy L; Somanathan S; Wilson JM
    J Virol; 2018 Oct; 92(20):. PubMed ID: 30089698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the Assembly-Activating Protein on Molecular Evolution of Synthetic Adeno-Associated Virus Capsids.
    Herrmann AK; Große S; Börner K; Krämer C; Wiedtke E; Gunkel M; Grimm D
    Hum Gene Ther; 2019 Jan; 30(1):21-35. PubMed ID: 29978729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy.
    Grimm D; Kay MA
    Curr Gene Ther; 2003 Aug; 3(4):281-304. PubMed ID: 12871018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vector Affinity and Receptor Distribution Define Tissue-Specific Targeting in an Engineered AAV Capsid.
    Martino RA; Wang Q; Xu H; Hu G; Bell P; Arroyo EJ; Sims JJ; Wilson JM
    J Virol; 2023 Jun; 97(6):e0017423. PubMed ID: 37199615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ocular Inflammatory Response to Intravitreal Injection of Adeno-Associated Virus Vector: Relative Contribution of Genome and Capsid.
    Timmers AM; Newmark JA; Turunen HT; Farivar T; Liu J; Song C; Ye GJ; Pennock S; Gaskin C; Knop DR; Shearman MS
    Hum Gene Ther; 2020 Jan; 31(1-2):80-89. PubMed ID: 31544533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors.
    Shi W; Arnold GS; Bartlett JS
    Hum Gene Ther; 2001 Sep; 12(14):1697-711. PubMed ID: 11560765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress in Bioengineering of Myotropic Adeno-Associated Viral Gene Therapy Vectors.
    Liu J; Koay TW; Maiakovska O; Zayas M; Grimm D
    Hum Gene Ther; 2023 May; 34(9-10):350-364. PubMed ID: 37082964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adeno-associated Virus (AAV) Assembly-Activating Protein Is Not an Essential Requirement for Capsid Assembly of AAV Serotypes 4, 5, and 11.
    Earley LF; Powers JM; Adachi K; Baumgart JT; Meyer NL; Xie Q; Chapman MS; Nakai H
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27852862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.